Bax-activating small molecules for cancer therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in activating the pro-apoptotic Bcl-2 protein Bax, as most human cancer cells are resistant to apoptosis due to an increased ratio of anti-apoptotic to pro-apoptotic Bcl-2 proteins, limiting the effectiveness of existing strategies that target interactions between these proteins.
Innovation Solution
Identification and use of small molecule compounds that bind to the hydrophobic groove of Bax, such as compound 106, to activate Bax by promoting its insertion into mitochondria, leading to Bax-dependent apoptosis in tumor cells, thereby inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules target anti-apoptotic Bcl-2 proteins to indirectly activate apoptosis, then apoptosis pathway activation is achieved, but tumor cell resistance persists due to the increased ratio of anti-apoptotic to pro-apoptotic Bcl-2 proteins
Solution Approach 1:
Instead of targeting anti-apoptotic Bcl-2 proteins to indirectly activate apoptosis, the invention directly targets pro-apoptotic Bax protein to activate it. This inverted approach bypasses the problem of anti-apoptotic protein overexpression by directly activating the executioner protein Bax, which then oligomerizes to permeabilize mitochondrial membranes and trigger apoptosis regardless of anti-apoptotic protein levels.
Solution Approach 2:
The invention extracts and targets the specific hydrophobic groove of Bax protein as the binding site for small molecules. By identifying and targeting this specific structural feature of Bax, the small molecules can directly activate Bax without being affected by the overall ratio of anti-apoptotic to pro-apoptotic proteins in the cell.
2Reliability
If Bax is activated by small molecules binding to its hydrophobic groove, then direct Bax-dependent apoptosis is achieved, but the complexity of identifying and developing such compounds increases
Solution Approach 1:
The invention focuses on the local hydrophobic groove structure of Bax protein as the specific binding site for small molecules. By targeting this localized structural feature rather than attempting to modulate the entire Bcl-2 protein family system, the compound development process is simplified while achieving reliable Bax-dependent apoptosis.
3Adaptability or versatility
If small molecules are designed to bind to Bax hydrophobic groove, then selective Bax activation occurs, but the difficulty of detecting and measuring Bax activation and apoptosis specificity increases
Solution Approach 1:
The invention employs fluorescence-based assays that provide real-time feedback on Bax activation status. The hydrophobic groove binding of small molecules to Bax can be detected through fluorescence changes, allowing researchers to monitor Bax activation dynamics and apoptosis specificity in real-time, thereby reducing the difficulty of detection and measurement.
Data Source
AI summary
The pro-apoptotic Bcl-2 protein Bax initiates apoptosis in almost all apoptotic paradigms. Agents facilitating disruptive Bax insertion into mitochondrial membranes have potential as cancer therapeutics. Small molecule compounds associating with the hydrophobic groove of the pro-apoptotic Bcl-2 protein Bax have been identified and found to promote Bax-dependent, but not Bak-dependent, apoptosis. The compounds alter Bax protein stability in vitro and promote Bax insertion into mitochondria, leading to Bax-dependent mitochondrial outer membrane permeabilization and apoptosis. The compounds activating the pro-apoptotic Bcl-2 protein Bax inhibit the growth of tumors by inducing apoptosis. Pharmaceutical compositions comprising the compounds that activate Bax and induce Bax-dependent apoptosis are useful as anti-cancer therapeutic agents alone or with other anti-cancer agents. Methods for inducing apoptosis and for treating cancer involve administering the compounds to a patient in need thereof.